MedTrace Logo

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

NCT07094893 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2026-01-14

No results posted yet for this study

Summary

The aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC. Further to this, the aim is to determine whether EREG/AREG status identifies right-PTL participants who will benefit from the addition of anti-EGFR therapy to first-line chemotherapy.

Conditions

Interventions

DRUG

Cetuximab (EGFR inhibitor)

Administration according to the labels of each IMP.

DRUG

Bevacizumab

Administration according to the labels of each IMP.

DRUG

Irinotecan (CPT-11)

Administration according to the labels of each IMP.

DRUG

Oxaliplatin

Administration according to the labels of each IMP.

DRUG

Leucovorin and 5-FU

Administration according to the labels of each IMP.

DRUG

Capecitabine

Administration according to the labels of each IMP.

Sponsors & Collaborators

  • Merck Serono International SA

    collaborator INDUSTRY

  • Gruppo Oncologico del Nord-Ovest

    lead OTHER

Principal Investigators

  • Chiara Cremolini, MD, PhD · Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-15
Primary Completion
2028-03-31
Completion
2030-03-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07094893 on ClinicalTrials.gov